Literature DB >> 26466568

Telomerase activation by genomic rearrangements in high-risk neuroblastoma.

Martin Peifer1,2, Falk Hertwig2,3, Frederik Roels2,3, Daniel Dreidax4, Moritz Gartlgruber4, Roopika Menon5,6, Andrea Krämer2,3, Justin L Roncaioli7, Frederik Sand2, Johannes M Heuckmann6, Fakhera Ikram2,3,8, Rene Schmidt9, Sandra Ackermann2,3, Anne Engesser3, Yvonne Kahlert3, Wenzel Vogel5, Janine Altmüller8, Peter Nürnberg2,8,10, Jean Thierry-Mieg11, Danielle Thierry-Mieg11, Aruljothi Mariappan2, Stefanie Heynck6, Erika Mariotti6, Kai-Oliver Henrich4, Christian Gloeckner6, Graziella Bosco1, Ivo Leuschner12, Michal R Schweiger13, Larissa Savelyeva4, Simon C Watkins14, Chunxuan Shao15, Emma Bell4, Thomas Höfer15, Viktor Achter16, Ulrich Lang16,17, Jessica Theissen3, Ruth Volland3, Maral Saadati18, Angelika Eggert19, Bram de Wilde20, Frank Berthold3, Zhiyu Peng21, Chen Zhao22, Leming Shi22, Monika Ortmann23, Reinhard Büttner23, Sven Perner5, Barbara Hero3, Alexander Schramm24, Johannes H Schulte19,25,26, Carl Herrmann27,28,29, Roderick J O'Sullivan7, Frank Westermann4, Roman K Thomas1,23, Matthias Fischer2,3,30.   

Abstract

Neuroblastoma is a malignant paediatric tumour of the sympathetic nervous system. Roughly half of these tumours regress spontaneously or are cured by limited therapy. By contrast, high-risk neuroblastomas have an unfavourable clinical course despite intensive multimodal treatment, and their molecular basis has remained largely elusive. Here we have performed whole-genome sequencing of 56 neuroblastomas (high-risk, n = 39; low-risk, n = 17) and discovered recurrent genomic rearrangements affecting a chromosomal region at 5p15.33 proximal of the telomerase reverse transcriptase gene (TERT). These rearrangements occurred only in high-risk neuroblastomas (12/39, 31%) in a mutually exclusive fashion with MYCN amplifications and ATRX mutations, which are known genetic events in this tumour type. In an extended case series (n = 217), TERT rearrangements defined a subgroup of high-risk tumours with particularly poor outcome. Despite a large structural diversity of these rearrangements, they all induced massive transcriptional upregulation of TERT. In the remaining high-risk tumours, TERT expression was also elevated in MYCN-amplified tumours, whereas alternative lengthening of telomeres was present in neuroblastomas without TERT or MYCN alterations, suggesting that telomere lengthening represents a central mechanism defining this subtype. The 5p15.33 rearrangements juxtapose the TERT coding sequence to strong enhancer elements, resulting in massive chromatin remodelling and DNA methylation of the affected region. Supporting a functional role of TERT, neuroblastoma cell lines bearing rearrangements or amplified MYCN exhibited both upregulated TERT expression and enzymatic telomerase activity. In summary, our findings show that remodelling of the genomic context abrogates transcriptional silencing of TERT in high-risk neuroblastoma and places telomerase activation in the centre of transformation in a large fraction of these tumours.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26466568      PMCID: PMC4881306          DOI: 10.1038/nature14980

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  29 in total

1.  A rapid micro chromatin immunoprecipitation assay (microChIP).

Authors:  John Arne Dahl; Philippe Collas
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

2.  Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome.

Authors:  Nathaniel D Heintzman; Rhona K Stuart; Gary Hon; Yutao Fu; Christina W Ching; R David Hawkins; Leah O Barrera; Sara Van Calcar; Chunxu Qu; Keith A Ching; Wei Wang; Zhiping Weng; Roland D Green; Gregory E Crawford; Bing Ren
Journal:  Nat Genet       Date:  2007-02-04       Impact factor: 38.330

Review 3.  Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins.

Authors:  Paula Martínez; María A Blasco
Journal:  Nat Rev Cancer       Date:  2011-03       Impact factor: 60.716

Review 4.  Alternative lengthening of telomeres: models, mechanisms and implications.

Authors:  Anthony J Cesare; Roger R Reddel
Journal:  Nat Rev Genet       Date:  2010-03-30       Impact factor: 53.242

5.  Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies.

Authors:  Inga Nagel; Monika Szczepanowski; José I Martín-Subero; Lana Harder; Takashi Akasaka; Ole Ammerpohl; Evelyne Callet-Bauchu; Randy D Gascoyne; Stefan Gesk; Doug Horsman; Wolfram Klapper; Aneela Majid; José A Martinez-Climent; Stephan Stilgenbauer; Holger Tönnies; Martin J S Dyer; Reiner Siebert
Journal:  Blood       Date:  2010-05-11       Impact factor: 22.113

6.  Direct recruitment of N-myc to target gene promoters.

Authors:  S M Mac; C A D'Cunha; P J Farnham
Journal:  Mol Carcinog       Date:  2000-10       Impact factor: 4.784

Review 7.  Neuroblastoma: biological insights into a clinical enigma.

Authors:  Garrett M Brodeur
Journal:  Nat Rev Cancer       Date:  2003-03       Impact factor: 60.716

8.  Rearrangement of upstream sequences of the hTERT gene during cellular immortalization.

Authors:  Yuanjun Zhao; Shuwen Wang; Evgenya Y Popova; Sergei A Grigoryev; Jiyue Zhu
Journal:  Genes Chromosomes Cancer       Date:  2009-11       Impact factor: 5.006

Review 9.  Neuroblastoma.

Authors:  John M Maris; Michael D Hogarty; Rochelle Bagatell; Susan L Cohn
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

10.  Identification of ALK as a major familial neuroblastoma predisposition gene.

Authors:  Yaël P Mossé; Marci Laudenslager; Luca Longo; Kristina A Cole; Andrew Wood; Edward F Attiyeh; Michael J Laquaglia; Rachel Sennett; Jill E Lynch; Patrizia Perri; Geneviève Laureys; Frank Speleman; Cecilia Kim; Cuiping Hou; Hakon Hakonarson; Ali Torkamani; Nicholas J Schork; Garrett M Brodeur; Gian P Tonini; Eric Rappaport; Marcella Devoto; John M Maris
Journal:  Nature       Date:  2008-08-24       Impact factor: 49.962

View more
  210 in total

1.  Telomere maintenance is pivotal for high-risk neuroblastoma.

Authors:  Falk Hertwig; Martin Peifer; Matthias Fischer
Journal:  Cell Cycle       Date:  2015-12-10       Impact factor: 4.534

Review 2.  Spontaneous regression of neuroblastoma.

Authors:  Garrett M Brodeur
Journal:  Cell Tissue Res       Date:  2018-01-05       Impact factor: 5.249

Review 3.  Stop pulling my strings - what telomeres taught us about the DNA damage response.

Authors:  Eros Lazzerini-Denchi; Agnel Sfeir
Journal:  Nat Rev Mol Cell Biol       Date:  2016-05-11       Impact factor: 94.444

4.  Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer.

Authors:  Manjie Xing; Wen Fong Ooi; Jing Tan; Aditi Qamra; Po-Hsien Lee; Zhimei Li; Chang Xu; Nisha Padmanabhan; Jing Quan Lim; Yu Amanda Guo; Xiaosai Yao; Mandoli Amit; Ley Moy Ng; Taotao Sheng; Jing Wang; Kie Kyon Huang; Chukwuemeka George Anene-Nzelu; Shamaine Wei Ting Ho; Mohana Ray; Lijia Ma; Gregorio Fazzi; Kevin Junliang Lim; Giovani Claresta Wijaya; Shenli Zhang; Tannistha Nandi; Tingdong Yan; Mei Mei Chang; Kakoli Das; Zul Fazreen Adam Isa; Jeanie Wu; Polly Suk Yean Poon; Yue Ning Lam; Joyce Suling Lin; Su Ting Tay; Ming Hui Lee; Angie Lay Keng Tan; Xuewen Ong; Kevin White; Steven George Rozen; Michael Beer; Roger Sik Yin Foo; Heike Irmgard Grabsch; Anders Jacobsen Skanderup; Shang Li; Bin Tean Teh; Patrick Tan
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

5.  Copy-number analysis and inference of subclonal populations in cancer genomes using Sclust.

Authors:  Yupeng Cun; Tsun-Po Yang; Viktor Achter; Ulrich Lang; Martin Peifer
Journal:  Nat Protoc       Date:  2018-05-24       Impact factor: 13.491

Review 6.  A second chance for telomerase reverse transcriptase in anticancer immunotherapy.

Authors:  Maurizio Zanetti
Journal:  Nat Rev Clin Oncol       Date:  2016-06-01       Impact factor: 66.675

7.  Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.

Authors:  Balakrishna Koneru; Gonzalo Lopez; Ahsan Farooqi; Karina L Conkrite; Thinh H Nguyen; Shawn J Macha; Apexa Modi; Jo Lynne Rokita; Eduardo Urias; Ashly Hindle; Heather Davidson; Kristyn Mccoy; Jonas Nance; Vanda Yazdani; Meredith S Irwin; Shengping Yang; David A Wheeler; John M Maris; Sharon J Diskin; C Patrick Reynolds
Journal:  Cancer Res       Date:  2020-04-14       Impact factor: 12.701

Review 8.  Regulation of CTNNB1 signaling in gastric cancer and stem cells.

Authors:  Shihori Tanabe; Kazuhiko Aoyagi; Hiroshi Yokozaki; Hiroki Sasaki
Journal:  World J Gastrointest Oncol       Date:  2016-08-15

9.  Repression of telomerase gene promoter requires human-specific genomic context and is mediated by multiple HDAC1-containing corepressor complexes.

Authors:  Yuanjun Zhao; Shuwen Wang; Fan Zhang; Mariano Russo; Steven B McMahon; Jiyue Zhu
Journal:  FASEB J       Date:  2016-12-09       Impact factor: 5.191

10.  The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.

Authors:  Sonja Textor; Felicitas Bossler; Kai-Oliver Henrich; Moritz Gartlgruber; Julia Pollmann; Nathalie Fiegler; Annette Arnold; Frank Westermann; Nina Waldburger; Kai Breuhahn; Sven Golfier; Mathias Witzens-Harig; Adelheid Cerwenka
Journal:  Oncoimmunology       Date:  2016-07-28       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.